Evidence map›Paper›PMID 40269760›Full record

Trial reportBMC medical research methodology2025

Visualizing a marker's degrees of necessity and of sufficiency in the predictiveness curve.

Andreas Gleiss

Registry-linked trialAbstract readAdaptive Clinical TrialClinical Trial, Phase IIClinical Trial, Phase III
In one paragraph

Trial report in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04351724 (A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04351724 phase2 / phase3unknown statusnot on this map

A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)

TypeinterventionalSponsorMedical University of ViennaRan2020 to 2022Enrolled500ConditionsCOVID-19ArmsChloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care, Rivaroxaban, Thromboprophylaxis
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Andreas GleissCenter for Medical Data Science, Institute of Clinical Biometrics, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. andreas.gleiss@meduniwien.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe degrees to which a factor is necessary or sufficient for an event have been proposed as generalizations of attributable risk based on simple functions of unconditional and conditional event probabilities. Predictiveness curves show the risk for an event, as derived by a model with one or more predictors, depending on risk percentiles that represent the predictors' distribution in the underlying population.

methodsConnections between the degrees of necessity and of sufficiency and explained variation on the one hand and the predictiveness curve on the other hand are mathematically proved and exemplified using data of in-hospital death of Covid- 19 patients.

resultsWe show that the degrees of necessity and of sufficiency can be represented as proportions of areas easily identifiable in the plot of the predictiveness curve. In addition, we show that the proportion of explained variation, a common measure of predictiveness and relative importance of prognostic factors, is also closely connected to these areas.

conclusionOur investigations demonstrate that the predictiveness curve extended by these new interpretations of areas provides a comprehensive evaluation of markers or sets of markers for prediction.

trial registrationAustrian Coronavirus Adaptive Clinical Trial (ACOVACT); ClinicalTrials.gov, identifier NCT04351724.

Indexed as

COVID-19Models, StatisticalBiomarkersHospital MortalityHumansMalePrognosisSARS-CoV-2BiomarkersExplained variationNecessityPredictiveness curveSufficiency

Identifiers

PMID40269760
PMCPMC12016328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.